Serotiny, Inc. has been acquired by Johnson & Johnson. Serotiny will continue to advance its mission to discover new engineered multi-domain proteins for application-tailored cell and gene therapies across a broad spectrum of therapeutic applications. The team is pleased to join Johnson & Johnson Innovative Medicine to continue exploring the potential of the discovery platform as a key capability for creating the next generation of cell and gene therapies.Read more...